Untitled

Abstract

In the last decades, diabetes has become one of the most prevalent health concerns worldwide. Diabetes is a metabolic disease that causes hyperglycemia and is associated with altered insulin production (type 1 diabetes) or with insulin-resistance (type 2 diabetes). The present work aims to point out the relevance of glipizide as an alternative treatment for type 2 diabetes and discuss the different delivery systems developed for this drug. With this in mind, we performed a nonsystematic search in different databases like PubMed, Google Scholar, Science Direct and the FDA's and some other web pages, using key words as search criterion. Because glipizide is a drug with a short elimination half-life, a dosage of two to three tablets per day is needed, depending on the therapeutic requirements of each patient. The as aforementioned has led different research groups to develop new delivery systems for this drug; among them are nanoparticles, nanosuspensions, microspheres, self-emulsifying systems, matrix tablets, osmotic tablets, and gastroretentive systems. The developed systems have been aimed at reducing the dosage frequency of glipizide, expecting to improve therapeutic adherence.INTRODUCTION: Diabetes (DBT) is a metabolic disease that causes hyperglycemia and is associated with altered insulin production (type 1 diabetes, DBT1) or with insulin resistance (type 2 diabetes, DBT2). Progression of the disease can induce malfunctioning of organs like the heart, kidneys and eyes 1 . DBT is one of the main causes of morbidity and mortality worldwide that affects ca. 463 million adults, of whom 79% live in low-or medium-income countries.